The study is intended to assess the safety and efficacy of SML’s experimental drug product, brostallicin. The trial will also be supported by the Sarcoma Foundation of America (SFA). Pharmatech will manage this sarcoma trial using its innovative Just-In-Time (JIT) approach. This streamlined approach was created to increase enrollment in clinical trials for rare cancer disease indications with narrow patient populations. Patient enrollment, through JIT, is further increased because a protocol can be rolled out to a large number of qualified research network sites with minimal expense of time and capital.
Matthew Alsante, executive director, SFA, said: “The collaboration allows for a superior coordination among key players in the clinical trial process. The patients come to the foundation through our sophisticated registry. The foundation takes the incidence data from the registry to communicate directly with the patients about the clinical trials available to them through partnerships with research management groups such as Pharmatech.”